AGG Talks: Government Insight for Life Sciences Leaders Podcast Series · Arnall Golden Gregory LLP
DOJ’s Shifting Enforcement: CPB Disbanding, Counterfeit Drug Focus, and Gender-Affirming Care Investigations
·17 min·1 clip
Counterfeit pain medication laced with illicit fentanyl is the DOJ's number one priority in counterfeit drug enforcement.
As heard by us
A measured look at how DOJ enforcement pressure reaches across the life sciences supply chain.
AGG Talks frames the discussion around three enforcement issues affecting life sciences: the Consumer Protection Branch's recent restructuring, DOJ's crackdown on counterfeit drugs, and increased attention to gender-affirming care.
Why you'd press play
You want a clear read on where DOJ enforcement pressure is moving next.
Listen to the show on